HRP20160039T1 - Modulatori aurora kinaze i postupak uporabe - Google Patents
Modulatori aurora kinaze i postupak uporabe Download PDFInfo
- Publication number
- HRP20160039T1 HRP20160039T1 HRP20160039TT HRP20160039T HRP20160039T1 HR P20160039 T1 HRP20160039 T1 HR P20160039T1 HR P20160039T T HRP20160039T T HR P20160039TT HR P20160039 T HRP20160039 T HR P20160039T HR P20160039 T1 HRP20160039 T1 HR P20160039T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyridinyl
- phenyl
- oxy
- amino
- nr15c
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 7
- 102000003989 Aurora kinases Human genes 0.000 title 1
- 108090000433 Aurora kinases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 39
- 125000005842 heteroatom Chemical group 0.000 claims 33
- 125000004432 carbon atom Chemical group C* 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 24
- -1 C2-10-alkynyl Chemical group 0.000 claims 23
- 229910052760 oxygen Inorganic materials 0.000 claims 23
- 125000005843 halogen group Chemical group 0.000 claims 18
- 229910052757 nitrogen Inorganic materials 0.000 claims 17
- 125000004122 cyclic group Chemical group 0.000 claims 15
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims 15
- 101100160255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YLR154C-H gene Proteins 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 14
- 125000001188 haloalkyl group Chemical group 0.000 claims 13
- 229920006395 saturated elastomer Polymers 0.000 claims 13
- 125000002619 bicyclic group Chemical group 0.000 claims 12
- 125000002950 monocyclic group Chemical group 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 10
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 10
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 10
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 10
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 10
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims 10
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 8
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 8
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 8
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 7
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 7
- 125000004043 oxo group Chemical group O=* 0.000 claims 7
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims 5
- 208000017604 Hodgkin disease Diseases 0.000 claims 5
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 5
- 206010042971 T-cell lymphoma Diseases 0.000 claims 5
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 5
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 5
- 229940043279 diisopropylamine Drugs 0.000 claims 5
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 claims 5
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 claims 5
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- IVUGFMLRJOCGAS-UHFFFAOYSA-N n-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine Chemical compound CC1=CSC(C=2C3=CC=CC=C3C(NC=3C=CC(OC=4C(=CC=CN=4)C=4N=C(N)N=CC=4)=CC=3)=NN=2)=C1 IVUGFMLRJOCGAS-UHFFFAOYSA-N 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims 2
- 206010016935 Follicular thyroid cancer Diseases 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 201000010208 Seminoma Diseases 0.000 claims 2
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 210000003679 cervix uteri Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- DZSJKDLABPVVOC-UHFFFAOYSA-N n-[4-[3-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-4-yl)pyridin-2-yl]oxyphenyl]-4-phenylphthalazin-1-amine Chemical compound N1CCC2=C1N=CC=C2C1=CC=CN=C1OC(C=C1)=CC=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 DZSJKDLABPVVOC-UHFFFAOYSA-N 0.000 claims 2
- ATKXTLSICZHQRT-UHFFFAOYSA-N n-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(3-fluoropiperidin-1-yl)phthalazin-1-amine Chemical compound NC1=NC=CC(C=2C(=NC=CC=2)OC=2C=CC(NC=3C4=CC=CC=C4C(N4CC(F)CCC4)=NN=3)=CC=2)=N1 ATKXTLSICZHQRT-UHFFFAOYSA-N 0.000 claims 2
- AJZHFGIIOVOHLB-UHFFFAOYSA-N n-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(5-methylpyridin-2-yl)phthalazin-1-amine Chemical compound N1=CC(C)=CC=C1C(C1=CC=CC=C11)=NN=C1NC(C=C1)=CC=C1OC1=NC=CC=C1C1=CC=NC(N)=N1 AJZHFGIIOVOHLB-UHFFFAOYSA-N 0.000 claims 2
- ITILROOSRBZSCL-UHFFFAOYSA-N n-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-cyclohexylphthalazin-1-amine Chemical compound NC1=NC=CC(C=2C(=NC=CC=2)OC=2C=CC(NC=3C4=CC=CC=C4C(C4CCCCC4)=NN=3)=CC=2)=N1 ITILROOSRBZSCL-UHFFFAOYSA-N 0.000 claims 2
- YMEFFUNEAVNRHI-UHFFFAOYSA-N n-[6-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxypyridin-3-yl]-4-(3-methylsulfonylphenyl)phthalazin-1-amine Chemical compound CS(=O)(=O)C1=CC=CC(C=2C3=CC=CC=C3C(NC=3C=NC(OC=4C(=CC=CN=4)C=4N=C(N)N=CC=4)=CC=3)=NN=2)=C1 YMEFFUNEAVNRHI-UHFFFAOYSA-N 0.000 claims 2
- GSVQVXMTNHZJLZ-UHFFFAOYSA-N n-[6-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxypyridin-3-yl]-4-(4-methylthiophen-2-yl)phthalazin-1-amine Chemical compound CC1=CSC(C=2C3=CC=CC=C3C(NC=3C=NC(OC=4C(=CC=CN=4)C=4N=C(N)N=CC=4)=CC=3)=NN=2)=C1 GSVQVXMTNHZJLZ-UHFFFAOYSA-N 0.000 claims 2
- KRXMQYCSEJJJAZ-UHFFFAOYSA-N n-[6-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxypyridin-3-yl]-4-(5-methylpyridin-2-yl)phthalazin-1-amine Chemical compound N1=CC(C)=CC=C1C(C1=CC=CC=C11)=NN=C1NC(C=N1)=CC=C1OC1=NC=CC=C1C1=CC=NC(N)=N1 KRXMQYCSEJJJAZ-UHFFFAOYSA-N 0.000 claims 2
- 208000007538 neurilemmoma Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 2
- 206010039667 schwannoma Diseases 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 208000001608 teratocarcinoma Diseases 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- PAFNYIIRZAUDMJ-LJQANCHMSA-N (1r)-1-[4-[4-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyanilino]phthalazin-1-yl]phenyl]ethanol Chemical compound C1=CC([C@H](O)C)=CC=C1C(C1=CC=CC=C11)=NN=C1NC(C=C1)=CC=C1OC1=NC=CC=C1C1=CC=NC(N)=N1 PAFNYIIRZAUDMJ-LJQANCHMSA-N 0.000 claims 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 claims 1
- YAVSSHJAJSPFLN-UHFFFAOYSA-N 1-[4-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyanilino]phthalazin-1-yl]piperidin-3-ol Chemical compound NC1=NC=CC(C=2C(=NC=CC=2)OC=2C=CC(NC=3C4=CC=CC=C4C(N4CC(O)CCC4)=NN=3)=CC=2)=N1 YAVSSHJAJSPFLN-UHFFFAOYSA-N 0.000 claims 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 claims 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims 1
- IGPYELCEVRSDHL-UHFFFAOYSA-N 4-(6-methylpyridin-2-yl)-n-[4-[3-[2-(3-piperazin-1-ylpropylamino)pyrimidin-4-yl]pyridin-2-yl]oxyphenyl]phthalazin-1-amine Chemical compound CC1=CC=CC(C=2C3=CC=CC=C3C(NC=3C=CC(OC=4C(=CC=CN=4)C=4N=C(NCCCN5CCNCC5)N=CC=4)=CC=3)=NN=2)=N1 IGPYELCEVRSDHL-UHFFFAOYSA-N 0.000 claims 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101100240520 Caenorhabditis elegans nhr-14 gene Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 101000742859 Homo sapiens Retinoblastoma-associated protein Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 102100038042 Retinoblastoma-associated protein Human genes 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N beta-hydroxyethanesulfonic acid Natural products OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000003971 isoxazolinyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- QANFGIQDRATYPL-UHFFFAOYSA-N n-[4-(2-methoxy-6-pyridin-4-ylphenoxy)phenyl]-4-phenylphthalazin-1-amine Chemical compound COC1=CC=CC(C=2C=CN=CC=2)=C1OC(C=C1)=CC=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 QANFGIQDRATYPL-UHFFFAOYSA-N 0.000 claims 1
- YZXAPZMJDNUBKX-UHFFFAOYSA-N n-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4,5-dimethyl-6-(4-methylthiophen-2-yl)pyridazin-3-amine Chemical compound CC1=CSC(C=2C(=C(C)C(NC=3C=CC(OC=4C(=CC=CN=4)C=4N=C(N)N=CC=4)=CC=3)=NN=2)C)=C1 YZXAPZMJDNUBKX-UHFFFAOYSA-N 0.000 claims 1
- LTPKKIFPRYCRAL-UHFFFAOYSA-N n-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(3-methyl-1,2-thiazol-5-yl)phthalazin-1-amine Chemical compound S1N=C(C)C=C1C(C1=CC=CC=C11)=NN=C1NC(C=C1)=CC=C1OC1=NC=CC=C1C1=CC=NC(N)=N1 LTPKKIFPRYCRAL-UHFFFAOYSA-N 0.000 claims 1
- WLFXBPRHQWJIRK-UHFFFAOYSA-N n-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-4-(6-methylpyridin-2-yl)phthalazin-1-amine Chemical compound CC1=CC=CC(C=2C3=CC=CC=C3C(NC=3C=CC(OC=4C(=CC=CN=4)C=4N=C(N)N=CC=4)=CC=3)=NN=2)=N1 WLFXBPRHQWJIRK-UHFFFAOYSA-N 0.000 claims 1
- SFYDPNZDOVODTA-UHFFFAOYSA-N n-[4-[3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxyphenyl]-6-phenyl-4-propylpyridazin-3-amine Chemical compound CCCC1=CC(C=2C=CC=CC=2)=NN=C1NC(C=C1)=CC=C1OC1=NC=CC=C1C1=CC=NC(N)=N1 SFYDPNZDOVODTA-UHFFFAOYSA-N 0.000 claims 1
- UIRHQMYDUQMYJL-UHFFFAOYSA-N n-[4-[3-(5-amino-1h-pyrazol-4-yl)pyridin-2-yl]oxy-3-fluorophenyl]-4-phenylphthalazin-1-amine Chemical compound NC1=NNC=C1C1=CC=CN=C1OC(C(=C1)F)=CC=C1NC(C1=CC=CC=C11)=NN=C1C1=CC=CC=C1 UIRHQMYDUQMYJL-UHFFFAOYSA-N 0.000 claims 1
- VAAYUYYHQZFLLE-UHFFFAOYSA-N n-[4-[3-(5-amino-1h-pyrazol-4-yl)pyridin-2-yl]oxyphenyl]-4-benzylphthalazin-1-amine Chemical compound NC1=NNC=C1C1=CC=CN=C1OC(C=C1)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=CC=C1 VAAYUYYHQZFLLE-UHFFFAOYSA-N 0.000 claims 1
- BARMVCVLUMVZPD-SVBPBHIXSA-N n-[4-[3-[2-[3-[(2s,5s)-2,5-dimethylmorpholin-4-yl]propylamino]pyrimidin-4-yl]pyridin-2-yl]oxyphenyl]-4-phenylphthalazin-1-amine Chemical compound C[C@H]1CO[C@@H](C)CN1CCCNC1=NC=CC(C=2C(=NC=CC=2)OC=2C=CC(NC=3C4=CC=CC=C4C(C=4C=CC=CC=4)=NN=3)=CC=2)=N1 BARMVCVLUMVZPD-SVBPBHIXSA-N 0.000 claims 1
- FOJXWIGXDIJDPW-UHFFFAOYSA-N n-[4-[3-[5-fluoro-2-[3-(4-methylpiperazin-1-yl)propylamino]pyrimidin-4-yl]pyridin-2-yl]oxyphenyl]-4-phenylphthalazin-1-amine Chemical compound C1CN(C)CCN1CCCNC1=NC=C(F)C(C=2C(=NC=CC=2)OC=2C=CC(NC=3C4=CC=CC=C4C(C=4C=CC=CC=4)=NN=3)=CC=2)=N1 FOJXWIGXDIJDPW-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000005968 oxazolinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000005267 prostate cell Anatomy 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000002755 pyrazolinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000002769 thiazolinyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (31)
1. Spoj Formule II:
[image]
ili njegov stereoizomer, tautomer, solvat ili farmaceutski prikladna sol, gdje svaki
od A1 i A2, nezavisno, je N ili CR9, uz uvjet da barem jedan od A1 i A2 je N;
svaki od B1, B2, B3 i B4, nezavisno, je N ili CR5, uz uvjet da ne više od dva od B1, B2, B3 i B4 su N;
C1 je CR10.
D1 je N ili CR11;
D2 je N ili CR12;
L1 je NR3, O, S ili CR3R3;
L2 je NR3, O ili S;
R1 je OR14, SR14, OR15, SR15, NR14R15, NR15R15, (CHR15)nR14, (CHR15)nR15 ili R15; alternativno R1 i R11 uzeti zajedno s atomima ugljika na koje su spojeni formiraju djelomično ili potpuno zasićeni 5- ili 6-eročlani prsten ugljikovih atoma koji po izboru obuhvaća 1-3 heteroatoma izabrana između O, N i S, i prsten je po izboru supstituiran nezavisno s 1-3 supstituenta od okso, R15, SR14, OR14, SR15, OR15, OC(O)R15, COOR15, C(O)R15, C(O)NR15R15, NR4R5 ili NR15R5;
R2 je H, halo, NO2, CN, C1-10alkil ili C1-10alkoksil;
svaki od R3, R4 i R9, nezavisno, je H;
svaki R5 je, nezavisno, SR14, OR14, SR15, OR15, NR14R15, NR15R15, C(O)R14, C(O)R15, COOR15, OC(O)R15, C(O)C(O)R15, C(O)NR14R15, C(O)NR15R15, NR15C(O)R14, NR15C(O)R15, NR15C(O)NR14R15, NR15C(O)NR15R15, NR15C(O)C(O)R15, NR15(COOR15), OC(O)NR15R15, S(O)2R14, S(O)2R15, S(O)2NR14R15, S(O)2NR15R15, NR15S(O)2NR15R15, NR15S(O)2R14, NR15S(O)2R15, NR15S(O)2NR14R15, NR15C(O)C(O)NR14R15, NR15C(O)C(O)NR15R15 ili R15;
R6 je R14;
svaki od R7 i R8, nezavisno, je R13, R14 ili R15;
alternativno, bilo koji od R7 i R8 uzet zajedno s atomima ugljika na koji su spojeni formira potpuno zasićeni ili djelomično ili potpuno nezasićeni 5- ili 6-eročlani prsten ugljikovih atoma koji po izboru obuhvaća 1-3 heteroatoma izabrana između O, N, ili S, i prsten je po izboru supstituiran nezavisno s 1-4 supstituenta od R13, R14 ili R15;
svaki od R10, R11 i R12, nezavisno, je SR14, OR14, SR15, OR15, NR14R15, NR15R15, C(O)R14, C(O)R15 ili R15;
R13 je SR14, OR14, SR15, OR15, NR14R15, NR15R15, C(O)R14, C(O)R15, OC(O)R14, OC(O)R15, COOR14, COOR15, C(O)NR14R15, C(O)NR15R15, NR15C(O)R14, NR15C(O)R15, C(O)C(O)R15, NR15C(O)NR14R15, NR15C(O)NR15R15, NR15C(O)C(O)R15, NR15(COOR14), NR15(COOR15), NR15C(O)C(O)NR14R15, NR15C(O)C(O)NR15R15, S(O)2R14, S(O)2R15, S(P)2NR14R15, S(O)2NR15R15 NR15S(O)2R14, NR15S(O)2R15, NR15S(O)2NR14R15 ili NR15S(O)2NR15R15;
R14 je djelomično ili potpuno zasićeni ili potpuno nezasićeni 5-8-eročlani monociklički, 6-12-eročlani biciklički, ili 7-14-eročlani triciklički prstenasti sustav, prstenasti sustav formiran od ugljikovih atoma po izboru obuhvaća 1-3 heteroatoma ako je monociklički, 1-6 heteroatoma ako je biciklički, ili 1-9 heteroatoma ako je triciklički, heteroatomi se izabiru između O, N, ili S, gdje je 0, 1, 2 ili 3 atoma svakog prstena po izboru supstituirano nezavisno s 1-5 supstituenta R15;
R15 je H, halo, haloalkil, haloalkoksil, okso, CN, OH, SH, NO2, NH2, acetil, C1-10-alkil, C2-10-alkenil, C2-10-alkinil, C3-10-cikloalkil, C4-10-cikloalkenil, C1-10-alkilamino-, C1-10-dialkilamino-, C1-10-alkoksil, C1-10-tioalkoksil ili zasićeni ili djelomično ili potpuno nezasićeni 5-8-eročlani monociklički, 6-12-eročlani biciklički, ili 7-14-eročlani triciklički prstenasti sustav, taj prstenasti sustav formiran od ugljikovih atoma po izboru obuhvaća 1-3 heteroatoma ako je monociklički, 1-6 heteroatoma ako je biciklički, ili 1-9 heteroatoma ako je triciklički, ti heteroatomi se izabiru između O, N, ili S, gdje je svaki od C1-10-alkil, C2-10-alkenil, C2-10-alkinil, C3-10-cikloalkil, C4-10-cikloalkenil, C1-10-alkilamino-, C1-10-dialkilamino-, C1-10-alkoksil, C1-10-tioalkoksil i prstena tog prstenastog sustava po izboru supstituiran nezavisno s 1-5 supstituenta od halo, haloalkil, CN, NO2, NH2, OH, okso, metil, metoksil, etil, etoksil, propil, propoksil, izopropil, ciklopropil, butil, izobutil, tert-butil, metilamin, dimetilamin, etilamin, dietilamin, propilamin, izopropilamin, dipropilamin, diizopropilamin, benzil ili fenil; i
n je 0, 1, 2, 3 ili 4;
uz uvjet da ne više od jednog od D1 i D2 je N.
2. Spoj prema zahtjevu 1, gdje
svaki od A1 i A2, nezavisno, je N;
svaki od B1, B2, B3 i B4, nezavisno, je N ili CR5, uz uvjet da ne više od jednog od B1, B2, B3 i B4 je N;
C1 je CR10;
D1 je N ili CR11;
D2 je N ili CR12;
L1 je NH, O ili S;
L2 je NH, O ili S; uz uvjet da oba L1 i L2 nisu ili O ili S;
R1 je H, halo, haloalkil, NO2, NH2, acetil, C1-10-alkil, C2-10-alkenil, C2-10-alkinil, C3-10-cikloalkil, C1-10-alkilamino-, C1-10-dialkilamino-, C1-10-alkoksil, C1-10-tioalkoksil, NHR14, NHR15, OR15 SR15 ili CH2R15;
R2 je H, halo, NO2, CN, C1-10alkil ili C1-10alkoksil;
svaki od R3, R4 i R9 je H;
svaki R5 je, nezavisno, SR15, OR15, NR15R15, C(O)R15, C(O)NR15R15, NR15C(O)R15, NR15C(O)NR15R15, NR15(COOR15), S(O)2R15, S(O)2NR15R15, NR15S(O)2NR15R15, NR15S(O)2R15, NR15C(O)C(O)NR14R15 ili R15;
svaki od R7 i R8, nezavisno, je R15;
alternativno, bilo koji od R7 i R8 uzet zajedno s atomima ugljika na koji su spojeni formira djelomično ili potpuno zasićeni 5- ili 6-eročlani prsten ugljikovih atoma koji po izboru obuhvaća 1-3 heteroatoma izabrana između O, N, ili S, i prsten je po izboru supstituiran nezavisno s 1-4 supstituenta od R13 ili R15; i
svaki od R10, R11 i R12, nezavisno, je R15.
3. Spoj prema zahtjevu 1 gdje,
R1 je NR14R15, NR15R15, (CHR15)nR14, (CHR15)nR15 ili R15; alternativno R1 i R11 uzeti zajedno s atomima ugljika na koje su spojeni formiraju djelomično ili potpuno zasićeni 5- ili 6-eročlani prsten ugljikovih atoma koji po izboru obuhvaća 1-3 heteroatoma izabrana između O, N i S, i prsten je po izboru supstituiran nezavisno s 1-3 supstituenta R15;
R2 je H, halo, CN, NO2, metil, metoksil, etil, etoksil, propil, propoksil, izopropil, butil, izobutil, tert-butil;
svaki od R3, R4 i R9 je H;
svaki R5, nezavisno, je H, halo, haloalkil, CN, NO2, NH2, OH, metil, metoksil, etil, etoksil, propil, propoksil, izopropil, ciklopropil, butil, izobutil, tert-butil, metilamin, dimetilamin, etilamin, dietilamin, propilamin, izopropilamin, dipropilamin ili diizopropilamin;
svaki od R7 i R8, nezavisno, je R15;
alternativno, bilo koji od R7 i R8 uzet zajedno s atomima ugljika na koje su spojeni formira djelomično ili potpuno zasićeni 5- ili 6-eročlani prsten ugljikovih atoma koji po izboru obuhvaća 1-3 heteroatoma izabrana između O, N, ili S, i prsten je po izboru supstituiran nezavisno s 1-4 supstituenta od R13, R14 ili R15; i
svaki od R10, R11 i R12, nezavisno, je H, halo, haloalkil, CN, NO2, NH2, OH, metil, metoksil, etil, etoksil, propil, propoksil, izopropil, ciklopropil, butil, izobutil, tert-butil, metilamin, dimetilamin, etilamin, dietilamin, propilamin, izopropilamin, dipropilamin ili diizopropilamin.
4. Spoj prema zahtjevu 1 gdje,
svaki od A1 i A2, nezavisno, je N; i
R7 i R8 uzeti zajedno s atomima ugljika na koje su spojeni formiraju potpuno nezasićeni 5- ili 6-eročlani prsten ugljikovih atoma koji po izboru obuhvaća 1-3 heteroatoma izabrana između O, N, ili S, i prsten je po izboru supstituiran nezavisno s 1-4 supstituenta od R13, R14 ili R15.
5. Spoj prema zahtjevu 4 gdje,
R6 je fenil, naftil, piridil, pirimidinil, piridazinil, piazinil, triazinil, kinolinil, dihidrokinolinil, tetrahidrokinolinil, izokinolinil, tetrahidroizokinolinil, kinazolinil, izokinazolinil, ftalazinil, tiofenil, furil, tetrahidrofuranil, pirolil, pirazolil, tieno-pirazolil, imidazolil, triazolil, tetrazolil, tiazolil, tiadiazolil, benzotiazolil, oksazolil, oksadiazolil, benzoksazolil, benzoksadiazolil, izoksazolil, izotiazolil, indolil, azaindolil, 2,3-dihidroindolil, izoindolil, indazolil, benzofuranil, benzotiofenil, benzimidazolil, imidazo-piridinil, purinil, benzotriazolil, oksazolinil, izoksazolinil, tiazolinil, pirolidinil, pirazolinil, morfolinil, piperidinil, piperazinil, piranil, dioksozinil, 2,3-dihidro-1,4-benzoksazinil, 1,3-benzodioksolil, ciklopropil, ciklobutil, azetidinil, ciklopentil, cikloheksil, cikloheptil ili piranil, svaki od kojih je po izboru supstituiran nezavisno s 1-5 supstituenta R15.
6. Spoj Formule II:
[image]
ili njegov stereoizomer, tautomer, solvat ili farmaceutski prikladna sol, gdje svaki
od A1 i A2, nezavisno, je N ili CR9, uz uvjet da barem jedan od A1 i A2 je N;
svaki od B1, B2, B3 i B4, nezavisno, je N ili CR5, uz uvjet da ne više od dva od B1, B2, B3 i B4 su N;
C1 je CH.
D1 je N;
D2 je CR12 gdje R12 je H, halo, NO2, CN, C1-10alkil ili C1-10alkoksil;;
L1 je NH, O ili S;
L2 je NH;
R1 je H, halo, haloalkil, acetil, C1-10-alkil ili NHR15;
svaki od R2, R3 i R4, nezavisno, je H, halo, C1-10alkil ili C1-10alkoksil;
R5 je, nezavisno, SR14, OR14, SR15, OR15, NR14R15, NR15R15, C(O)R14, C(O)R15, COOR15, OC(O)R15, C(O)C(O)R15, C(O)NR14R15, C(O)NR15R15, NR15C(O)R14, NR15C(O)R15, NR15C(O)NR14R15, NR15C(O)NR15R15, NR15C(O)C(O)R15, NR15(COOR15), OC(O)NR15R15, S(O)2R14, S(O)2R15, S(O)2NR14R15, S(O)2NR15R15, NR15S(O)2NR15R15, NR15S(O)2R14, NR15S(O)2R15, NR15S(O)2NR14R15, NR15C(O)C(O)NR14R15, NR15C(O)C(O)NR15R15 ili R15;
R6 je R14;
R7 i R8 uzeti zajedno s atomima ugljika na koje su spojeni formiraju djelomično ili potpuno nezasićeni 5- ili 6-eročlani prsten ugljikovih atoma koji po izboru obuhvaća 1-3 heteroatoma izabrana između O, N, ili S, i prsten je po izboru supstituiran nezavisno s 1-4 supstituenta od R13 ili R15;
R9 je SR14, OR14, SR15, OR15, NR14R15, NR15R15, C(O)R14, C(O)R15 ili R15;
R13 je SR14, OR14, SR15, OR15, NR14R15, NR15R15, C(O)R14, C(O)R15, OC(O)R14, OC(O)R15, COOR14, COOR15, C(O)NR14R15, C(O)NR15R15, NR15C(O)R14, NR15C(O)R15, C(O)C(O)R15, NR15C(O)NR14R15, NR15C(O)NR15R15, NR15C(O)C(O)R15, NR15(COOR14), NR15(COOR15), NR15C(O)C(O)NR14R15, NR15C(O)C(O)NR15R15, S(O)2R14, S(O)2R15, S(O)2NR14R15, S(O)2NR15R15 NR15S(O)2R14, NR15S(O)2R15, NR15S(O)2NR14R15 ili NR15S(O)2NR15R15;
R14 je djelomično ili potpuno zasićeni ili potpuno nezasićeni 5-8-eročlani monociklički, 6-12-eročlani biciklički, ili 7-14-eročlani triciklički prstenasti sustav, prstenasti sustav formiran od ugljikovih atoma po izboru obuhvaća 1-3 heteroatoma ako je monociklički, 1-6 heteroatoma ako je biciklički, ili 1-9 heteroatoma ako je triciklički, heteroatomi se izabiru između O, N, ili S, gdje je 0, 1, 2 ili 3 atoma svakog prstena po izboru supstituirano nezavisno s 1-5 supstituenta R15; i
R15 je H, halo, haloalkil, haloalkoksil, okso, CN, OH, SH, NO2, NH2, acetil, C1-10-alkil, C2-10-alkenil, C2-10-alkinil, C3-10-cikloalkil, C4-10-cikloalkenil, C1-10-alkilamino-, C1-10-dialkilamino-, C1-10-alkoksil, C1-10-tioalkoksil ili zasićeni ili djelomično ili potpuno nezasićeni 5-8-eročlani monociklički, 6-12-eročlani biciklički, ili 7-14-eročlani triciklički prstenasti sustav, taj prstenasti sustav formiran od ugljikovih atoma po izboru obuhvaća 1-3 heteroatoma ako je monociklički, 1-6 heteroatoma ako je biciklički, ili 1-9 heteroatoma ako je triciklički, ti heteroatomi se izabiru između O, N, ili S, gdje je svaki od C1-10-alkil, C2-10-alkenil, C2-10-alkinil, C3-10-cikloalkil, C4-10-cikloalkenil, C1-10-alkilamino-, C1-10-dialkilamino-, C1-10-alkoksil, C1-10-tioalkoksil i prstena tog prstenastog sustava po izboru supstituiran nezavisno s 1-5 supstituenta od halo, haloalkil, CN, NO2, NH2, OH, okso, metil, metoksil, etil, etoksil, propil, propoksil, izopropil, ciklopropil, butil, izobutil, tert-butil, metilamin, dimetilamin, etilamin, dietilamin, propilamin, izopropilamin, dipropilamin, diizopropilamin, benzil ili fenil.
7. Spoj prema zahtjevu 6,
gdje svaki od R3 i R4, nezavisno, je H.
8. Postupak za pripremu spoja prema zahtjevima 1 ili 6, postupak obuhvaća korak reakcije spoja Formule A
[image]
sa spojem Formule B
[image]
gdje su B1, B2, B3, B4, C1, D1, D2, L1, R1, R2, R3 i R4 u spoju formule A te A1, A2 i R6, R7 i R8 u spoju formule B kako su definirani u zahtjevima 1 ili 6, i X je halogen, radi pripreme spoja Formule II.
9. Spoj Formule III:
[image]
ili njegov stereoizomer, tautomer, solvat ili farmaceutski prikladna sol, gdje svaki
od A1 i A2, nezavisno, je N ili CR9, uz uvjet da barem jedan od A1 i A2 je N;
svaki od B1, B2, B3 i B4, nezavisno, je N ili CR5, uz uvjet da ne više od dva od B1, B2, B3 i B4 su N;
C1 je N ili CR10.
L1 je O, S, C(O), S(O), SO2 ili CR3R3;
L2 je NR3, O, S ili CR3R3;
R1 je OR14, SR14, OR15, SR15, NR14R15, NR15R15, (CHR15)nR14, (CHR15)nR15 ili R15; alternativno R1 i R11 uzeti zajedno s atomima ugljika na koje su spojeni formiraju djelomično ili potpuno zasićeni 5- ili 6-eročlani prsten ugljikovih atoma koji po izboru obuhvaća 1-3 heteroatoma izabrana između O, N i S, i prsten je po izboru supstituiran nezavisno s 1-3 supstituenta od R15, SR14, OR14, SR15, OR15, OC(O)R15, COOR15, C(O)R15, C(O)NR15R15, NR14R15 ili NR15R15;
R2 je SR14, OR14, SR15, OR15, NR14R15, NR15R15, C(O)R14, C(O)R15, COOR15, OC(O)R15, C(O)C(O)R15, C(O)NR14R15, C(O)NR15R15, NR15C(O)R14, NR15C(O)R15, NR15C(O)NR14R15, NR15C(O)NR15R15, NR15C(O)C(O)R15, NR15(COOR15), OC(O)NR15R15, S(O)2R14, S(O)2R15, S(O)2NR14R15, S(O)2NR15R15, NR15S(O)2NR14R15 NR15S(O)2NR15R15, NR15S(O)2R14, NR15S(O)2R15 ili R15;
svaki od R3i R4, nezavisno, je SR14, OR14, SR15, OR15, NR14R15, NR15R15, C(O)R14, C(O)R15 ili R15;
svaki R5 je, nezavisno, SR14, OR14, SR15, OR15, NR14R15, NR15R15, C(O)R14, C(O)R15, COOR15, OC(O)R15, C(O)C(O)R15, C(O)NR14R15, C(O)NR15R15, NR15C(O)R14, NR15C(O)R15, NR15C(O)NR14R15, NR15C(O)NR15R15, NR15C(O)C(O)R15, NR15(COOR15), OC(O)NR15R15, S(O)2R14, S(O)2R15, S(O)2NR14R15, S(O)2NR15R15, NR15S(O)2NR15R15, NR15S(O)2R14, NR15S(O)2R15, NR15S(O)2NR14R15, NR15C(O)C(O)NR14R15, NR15C(O)C(O)NR15R15 ili R15;
R6 je R14;
svaki od R7 i R8, nezavisno, je R13, R14 ili R15;
alternativno, bilo koji od R7 i R8 uzet zajedno s atomima ugljika na koji su spojeni formira potpuno zasićeni ili djelomično ili potpuno nezasićeni 5- ili 6-eročlani prsten ugljikovih atoma koji po izboru obuhvaća 1-3 heteroatoma izabrana između O, N, ili S, i prsten je po izboru supstituiran nezavisno s 1-4 supstituenta od R13, R14 ili R15;
svaki od R9, R10, R11 i R12, nezavisno, je SR14, OR14, SR15, OR15, NR14R15, NR15R15, C(O)R14, C(O)R15 ili R15;
R13 je SR14, OR14, SR15, OR15, NR14R15, NR15R15, C(O)R14, C(O)R15, OC(O)R14, OC(O)R15, COOR14, COOR15, C(O)NR14R15, C(O)NR15R15, NR15C(O)R14, NR15C(O)R15, C(O)C(O)R15, NR15C(O)NR14R15, NR15C(O)NR15R15, NR15C(O)C(O)R15, NR15(COOR14), NR15(COOR15), NR15C(O)C(O)NR14R15, NR15C(O)C(O)NR15R15, S(O)2R14, S(O)2R15, S(O)2NR14R15, S(O)2NR15R15 NR15S(O)2R14, NR15(O)2R15, NR15S(O)2NR14R15 ili NR15S(O)2NR15R15;
R14 je djelomično ili potpuno zasićeni ili potpuno nezasićeni 5-8-eročlani monociklički, 6-12-eročlani biciklički, ili 7-14-eročlani triciklički prstenasti sustav, prstenasti sustav formiran od ugljikovih atoma po izboru obuhvaća 1-3 heteroatoma ako je monociklički, 1-6 heteroatoma ako je biciklički, ili 1-9 heteroatoma ako je triciklički, heteroatomi se izabiru između O, N, ili S, gdje je 0, 1, 2 ili 3 atoma svakog prstena po izboru supstituirano nezavisno s 1-3 supstituenta R15;
R15 je H, halo, haloalkil, haloalkoksil, okso, CN, OH, SH, NO2, NH2, acetil, C1-10-alkil, C2-10-alkenil, C2-10-alkinil, C3-10-cikloalkil, C4-10-cikloalkenil, C1-10-alkilamino-, C1-10-dialkilamino-, C1-10-alkoksil, C1-10-tioalkoksil ili zasićeni ili djelomično ili potpuno nezasićeni 5-8-eročlani monociklički, 6-12-eročlani biciklički, ili 7-14-eročlani triciklički prstenasti sustav, taj prstenasti sustav formiran od ugljikovih atoma po izboru obuhvaća 1-3 heteroatoma ako je monociklički, 1-6 heteroatoma ako je biciklički, ili 1-9 heteroatoma ako je triciklički, ti heteroatomi se izabiru između O, N, ili S, gdje je svaki od C1-10-alkil, C2-10-alkenil, C2-10-alkinil, C3-10-cikloalkil, C4-10-cikloalkenil, C1-10-alkilamino-, C1-10-dialkilamino-, C1-10-alkoksil, C1-10-tioalkoksil i prstena tog prstenastog sustava po izboru supstituiran nezavisno s 1-5 supstituenta od halo, haloalkil, CN, NO2, NH2, OH, okso, metil, metoksil, etil, etoksil, propil, propoksil, izopropil, ciklopropil, butil, izobutil, tert-butil, metilamin, dimetilamin, etilamin, dietilamin, propilamin, izopropilamin, dipropilamin, diizopropilamin, benzil ili fenil; i
n je 0, 1, 2, 3 ili 4.
10. Postupak za pripremu spoja prema zahtjevu 9, postupak obuhvaća korak reakcije spoja Formule A’
[image]
sa spojem Formule B
[image]
gdje su B1, B2, B3, B4, C1, L1, R1, R2, R3 i R4 u spoju formule A' te A1, A2 i R6, R7 i R8 u spoju formule B kako su definirani u zahtjevu 9, i X je halogen, radi pripreme spoja Formule III.
11. Spoj ili njegova farmaceutski prikladna sol, izabran između:
’2-(4-(4-((4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)amino)-1-ftalazinil)fenil)etanol;
’4-fenil-N-(6-((3-(2-((3-(1-piperidinil)propil)amino)-4-pirimidinil)-2-piridinil)oksi)-3-piridinil)-1-ftalazinamin;
’N-(4-((3-(2-((3-(4-metil-1-piperazinil)propil)amino)-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(6-metil-2-piridinil)-1-ftalazinamin;
’4-(6-metil-2-piridinil)-N-(4-((3-(2-((3-(1-piperazinil)propil)amino)-4-pirimidinil)-2-piridinil)oksi)fenil)-1-ftalazinamin;
’N-(4-((3-(5-fluoro-2-((3-(4-metil-1-piperazinil)propil)amino)-4-pirimidinil)-2-piridinil)oksi)fenil)-4-fenil-1-ftalazinamin;
’N-(4-((3-(3-amino-1H-pirazol-4-il)-2-piridinil)oksi)fenil)-4-(4-metilfenil)-1-ftalazinamin;
’N-(4-((3-(3-amino-1H-pirazol-4-il)-2-piridinil)oksi)fenil)-4-(fenilmetil)-1-ftalazinamin;
’N-(4-((3-(3-amino-1H-pirazol-4-il)-2-piridinil)oksi)fenil)-4-feniltieno[2,3-d]piridazin-7-amin;
’N-(4-((3-(3-amino-1H-pirazol-4-il)-2-piridinil)oksi)-3-fluorofenil)-4-fenil-1-ftalazinamin; i
’N-(4-((3-(2-((3-((2S,5S)-2,5-dimetil-4-morfolinil)propil)amino)-4-pirimidinil)-2-piridinil)oksi)fenil)-4-fenil-1-ftalazinamin.
12. Spoj prema zahtjevu 1, ili njegova farmaceutski prikladna sol, izabran između:
’N-(5-((3-(2-(metilamino)-4-pirimidinil)-2-piridinil)oksi)-2-piridinil)-4-fenil-1-ftalazinamin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-fenilfuro[2,3-d]piridazin-7-amin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(3-metil-5-izotiazolil)-1-ftalazinamin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(2,6-bis(metiloksi)fenil)-1-ftalazinamin;
’(1R)-1 -(4-(4-((4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)amino)-1-ftalazinil)fenil)etanol;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4,5-dimetil-6-(4-metil-2-tienil)-3-piridazinamin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-fenil-1-izokinolinamin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(4-metil-2-tienil)-1-izokinolinamin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(6-metil-2-piridinil)-1-ftalazinamin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-cikloheksil-1-ftalazinamin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(3-fluoro-1-piperidinil)-1-ftalazinamin;
’4-(2-((4-((4-fenil-1-ftalazinil)amino)fenil)oksi)-3-piridinil)-1,3-dihidro-2H-pirolo[2,3-b]piridin-2-on;
’4-(4-metil-1,3-tiazol-2-il)-N-(4-((3-(5,6,7,8-tetrahidro-1,8-naftiridin-4-il)-2-piridinil)oksi)fenil)-1-ftalazinamin;
’N-(4-((3-(2,3-dihidro-1H-pirolo[2,3-b]piridin-4-il)-2-piridinil)oksi)fenil)-4-fenil-1-ftalazinamin;
’N-(6-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)-3-piridinil)-4-(5-metil-2-piridinil)-1-ftalazinamin;
’N-(6-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)-3-piridinil)-4-(3-(metilsulfonil)fenil)-1-ftalazinamin;
’N-(6-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)-3-piridinil)-4-(4-metil-2-tienil)-1-ftalazinamin;
’1-(4-((4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)amino)-1-ftalazinil)-3-piperidinol;
’2-(4-((6-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)-3-piridinil)amino)-1-ftalazinil)fenol;
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(5-metil-2-piridinil)-1-ftalazinamin;
’2-((4-((4-(4-metil-2-tienil)-1-ftalazinil)amino)fenil)oksi)-3,4’-bipiridin-2’-amin;
’2-((4-((4-etil-6-fenil-3-piridazinil)amino)fenil)oksi)-3,4’-bipiridin-2’-amin;
’2-((4-((4-metil-6-(4-metil-1,3-tiazol-2-il)-3-piridazinil)amino)fenil)oksi)-3,4’-bipiridin-2’-amin;
’2-((4-((4-(2-(metiloksi)fenil)-1-ftalazinil)amino)fenil)oksi)-3,4’-bipiridin-2’-amin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-6-fenil-4-propil-3-piridazinamin; i
’N-(4-((2-(metiloksi)-6-(4-piridinil)fenil)oksi)fenil)-4-fenil-1-ftalazinamin.
13. Spoj prema zahtjevu 1 ili 12, ili njegova farmaceutski prikladna sol, izabran između:
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(3-metil-5-izotiazolil)-1-ftalazinamin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(2,6-bis(metiloksi)fenil)-1-ftalazinamin;
"N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(6-metil-2-piridinil)-1-ftalazinamin; i
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-cikloheksil-1-ftalazinamin.
14. Spoj prema zahtjevu 1 ili 12, ili njegova farmaceutski prikladna sol, izabran između:
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(3-fluoro-1-piperidinil)-1-ftalazinamin;
N-(4-((3-(2,3-dihidro-1H-pirolo[2,3-b]piridin-4-il)-2-piridinil)oksi)fenil)-4-fenil-1-ftalazinamin;
N-(6-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)-3-piridinil)-4-(5-metil-2-piridinil)-1-ftalazinamin;
N-(6-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)-3-piridinil)-4-(3-(metilsulfonil)fenil)-1-ftalazinamin;
N-(6-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)-3-piridinil)-4-(4-metil-2-tienil)-1-ftalazinamin;
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamin;
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(5-metil-2-piridinil)-1-ftalazinamin;
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-6-fenil-4-propil-3-piridazinamin; i
N-(4-((2-(metiloksi)-6-(4-piridinil)fenil)oksi)fenil)-4-fenil-1-ftalazinamin.
15. Spoj prema zahtjevu 1 ili 12, ili njegova farmaceutski prikladna sol, izabran između:
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(3-metil-5-izotiazolil)-1-ftalazinamin;
’N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(2,6-bis(metiloksi)fenil)-1-ftalazinamin;
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(6-metil-2-piridinil)-1-ftalazinamin;
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-cikloheksil-1-ftalazinamin;
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(3-fluoro-1-piperidinil)-1-ftalazinamin;
N-(6-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)-3-piridinil)-4-(5-metil-2-piridinil)-1-ftalazinamin;
N-(6-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)-3-piridinil)-4-(3-(metilsulfonil)fenil)-1-ftalazinamin;
N-(6-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)-3-piridinil)-4-(4-metil-2-tienil)-1-ftalazinamin;
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamin; i
N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oksi)fenil)-4-(5-metil-2-piridinil)-1-ftalazinamin.
16. Lijek koji sadrži učinkovitu dozirnu količinu spoja prema bilo kojem od zahtjeva 1-15 i farmaceutski prikladan nosač.
17. Spoj prema bilo kojem od zahtjeva 1-15 za uporabu u smanjenju veličine solidnog tumora ili za uporabu u liječenju raka, hematološkog tumora ili poremećaja stanične proliferacije u subjekta.
18. Uporaba spoja prema bilo kojem od zahtjeva 1-7, 9, 11-15 za pripremu lijeka za smanjenje veličine solidnog tumora ili za uporabu u liječenju raka, hematološkog tumora ili poremećaja stanične proliferacije u subjekta.
19. Spoj prema bilo kojem od zahtjeva 1-7, 9, 11-15 za uporabu u liječenju jednog ili više između (a) solidnog ili hematološki nastalog tumora izabranog između raka mjehura, dojke, kolona, bubrega, jetre, raka malih stanica pluća, jednjaka, žučnog mjehura, jajnika, gušterače, želuca, cerviksa, štitnjače, prostate i kože, (b) hematopoetskog tumora limfoidne linije izabranog između leukemije, akutne limfocitne leukemije, akutne limfoblastične leukemije, B-staničnog limfoma, T-staničnog limfoma, Hodgkinovog limfoma, ne-Hodgkinovog limfoma, limfoma vlasastih stanica i Burkittovog limfoma, (c) hematopoetskog tumora mijeloidne linije izabranog između akutne i kronične mijelogenične leukemije, mijelodisplastičnog sindroma i promijelocitne leukemije (d) tumora mezenhimalnog porijekla izabranog između fibrosarkoma i rabdomiosarkoma, (e) tumora središnjeg i perifernog živčanog sustava izabranog između astrocitoma, neuroblastoma, glioma i švanoma, ili (f) melanoma, seminoma, teratokarcinoma, osteosarkoma, pigmentne kseroderme, keratoksantoma, folikularnog raka štitnjače ili Kaposijevog sarkoma.
20. Uporaba spoja prema bilo kojem od zahtjeva 1-7, 9, 11-15 za pripremu lijeka za liječenje jednog ili više između (a) solidnog ili hematološki nastalog tumora izabranog između raka mjehura, dojke, kolona, bubrega, jetre, raka malih stanica pluća, jednjaka, žučnog mjehura, jajnika, gušterače, želuca, cerviksa, štitnjače, prostate i kože, (b) hematopoetskog tumora limfoidne linije izabranog između leukemije, akutne limfocitne leukemije, akutne limfoblastične leukemije, B-staničnog limfoma, T-staničnog limfoma, Hodgkinovog limfoma, ne-Hodgkinovog limfoma, limfoma vlasastih stanica i Burkittovog limfoma, (c) hematopoetskog tumora mijeloidne linije izabranog između akutne i kronične mijelogenične leukemije, mijelodisplastičnog sindroma i promijelocitne leukemije (d) tumora mezenhimalnog porijekla izabranog između fibrosarkoma i rabdomiosarkoma, (e) tumora središnjeg i perifernog živčanog sustava izabranog između astrocitoma, neuroblastoma, glioma i švanoma, ili (f) melanoma, seminoma, teratokarcinoma, osteosarkoma, pigmentne kseroderme, keratoksantoma, folikularnog raka štitnjače ili Kaposijevog sarkoma.
21. Spoj prema bilo kojem od zahtjeva 1-7, 12, 14 i 15 koji ima kemijsku strukturu
[image]
ili njegova farmaceutski prikladna sol.
22. Farmaceutski prikladan oblik soli spoja prema zahtjevu 21.
23. Spoj prema zahtjevu 22, gdje farmaceutski prikladan oblik soli jest oblik soli od sulfonske kiseline izabran između soli metansulfonske kiseline, soli etansulfonske kiseline, soli etandisulfonske kiseline, soli benzensulfonske kiseline, soli hidroksietansulfonske kiseline ili soli toluensulfonske kiseline.
24. Farmaceutski pripravak koji sadrži spoj prema zahtjevu 21, ili njegovu farmaceutski prikladnu sol, i farmaceutski prikladnu pomoćnu tvar.
25. Farmaceutski pripravak koji sadrži spoj prema bilo kojem od zahtjeva 11-15 i 21-23, i farmaceutski prikladnu pomoćnu tvar.
26. Spoj prema bilo kojem od zahtjeva 21-23 za uporabu u liječenju jednog raka ili više njih izabranih između raka mjehura, raka dojke, raka kolona, raka bubrega, raka jetre, raka pluća, raka jednjaka, raka žučnog mjehura, raka jajnika, raka gušterače, raka želuca, raka cerviksa, raka štitnjače, raka prostate i raka kože.
27. Lijek koji sadrži učinkovitu dozirnu količinu spoja prema bilo kojem od zahtjeva 1-7, 12, 14 i 15 koji ima strukturu:
[image]
ili njegovu farmaceutski prikladnu sol, i farmaceutski prikladan nosač.
28. Spoj prema bilo kojem od zahtjeva 1-7, 12, 14 i 15 koji ima strukturu:
[image]
ili njegova farmaceutski prikladna sol, za uporabu u liječenju jednog ili više između (a) hematopoetskog tumora limfoidne linije izabranog između leukemije, akutne limfocitne leukemije, akutne limfoblastične leukemije, B-staničnog limfoma, T-staničnog limfoma, Hodgkinovog limfoma, ne-Hodgkinovog limfoma, limfoma vlasastih stanica i Burkittovog limfoma, ili (b) hematopoetskog tumora mijeloidne linije izabranog između akutne i kronične mijelogenične leukemije, mijelodisplastičnog sindroma i promijelocitne leukemije.
29. Spoj prema bilo kojem od zahtjeva 1-7, 12, 14 i 15 koji ima strukturu:
[image]
ili njegova farmaceutski prikladna sol, za uporabu prema zahtjevu 29 u liječenju jednog ili više između (a) akutne mijelogenične leukemije (AML), kronične mijelogenične leukemije (CML), akutne limfocitne leukemije (ALL), B-staničnog limfoma, T-staničnog limfoma, Hodgkinovog limfoma, ne-Hodgkinovog limfoma ili mijelodisplastičnog sindroma (MDS).
30. Spoj koji ima strukturu:
[image]
ili njegova farmaceutski prikladna sol, za uporabu prema zahtjevu 29 u liječenju B-staničnog limfoma, T-staničnog limfoma, Hodgkinovog limfoma i ne-Hodgkinovog limfoma.
31. Postupak za pripremu spoja prema bilo kojem od zahtjeva s 1-7, 12, 14 i 15 koji ima strukturu
[image]
ili njegove farmaceutski prikladne soli, postupak obuhvaća korak reakcije spoja
[image]
sa spojem
[image]
gdje X je halogen.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76167506P | 2006-01-23 | 2006-01-23 | |
US11/655,642 US7560551B2 (en) | 2006-01-23 | 2007-01-18 | Aurora kinase modulators and method of use |
PCT/US2007/001714 WO2007087276A1 (en) | 2006-01-23 | 2007-01-22 | Aurora kinase modulators and method of use |
EP07716912.6A EP1984353B1 (en) | 2006-01-23 | 2007-01-22 | Aurora kinase modulators and method of use |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160039T1 true HRP20160039T1 (hr) | 2016-02-12 |
Family
ID=40849087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160039TT HRP20160039T1 (hr) | 2006-01-23 | 2016-01-13 | Modulatori aurora kinaze i postupak uporabe |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1984353B1 (hr) |
JP (2) | JP5280862B2 (hr) |
KR (2) | KR101332975B1 (hr) |
AU (2) | AU2007208351C1 (hr) |
BR (1) | BRPI0706684A2 (hr) |
CA (1) | CA2637658C (hr) |
CR (1) | CR10213A (hr) |
DK (1) | DK1984353T3 (hr) |
EA (1) | EA018128B1 (hr) |
ES (1) | ES2502790T3 (hr) |
GE (1) | GEP20125643B (hr) |
HK (1) | HK1167140A1 (hr) |
HR (1) | HRP20160039T1 (hr) |
HU (1) | HUE028504T2 (hr) |
IL (1) | IL192812A (hr) |
MA (1) | MA30224B1 (hr) |
MY (1) | MY161884A (hr) |
NO (1) | NO20083639L (hr) |
NZ (1) | NZ569815A (hr) |
TN (1) | TNSN08310A1 (hr) |
WO (1) | WO2007087276A1 (hr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5280862B2 (ja) * | 2006-01-23 | 2013-09-04 | アムジエン・インコーポレーテツド | オーロラキナーゼ調節剤および使用方法 |
CA2682504C (en) * | 2007-04-05 | 2012-10-30 | Amgen Inc. | Aurora kinase modulators and method of use |
MX2010010151A (es) * | 2008-03-20 | 2010-10-25 | Amgen Inc | Moduladores de cinasa aurora y metodo de uso. |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
CA2732101C (en) * | 2008-08-04 | 2013-09-17 | Amgen Inc. | Aurora kinase modulators and methods of use |
WO2010019473A1 (en) | 2008-08-14 | 2010-02-18 | Amgen Inc. | Aurora kinase modulators and methods of use |
ES2397934T3 (es) | 2008-12-17 | 2013-03-12 | Amgen Inc. | Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10 |
UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
WO2011031842A1 (en) * | 2009-09-11 | 2011-03-17 | Amgen Inc. | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
KR20160035613A (ko) | 2011-03-23 | 2016-03-31 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
AU2014357545B2 (en) * | 2013-12-03 | 2018-10-25 | Amgen Inc. | Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof |
MA41562B1 (fr) | 2015-06-03 | 2019-05-31 | Bristol Myers Squibb Co | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires |
WO2017047602A1 (ja) | 2015-09-18 | 2017-03-23 | 科研製薬株式会社 | ビアリール誘導体及びそれを含有する医薬 |
JP7032903B2 (ja) * | 2016-10-12 | 2022-03-09 | 田辺三菱製薬株式会社 | スルホンアミド化合物の製造方法 |
CN109384782A (zh) * | 2017-08-04 | 2019-02-26 | 厦门大学 | 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 |
WO2020049208A1 (es) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida |
CN111302948A (zh) * | 2020-04-13 | 2020-06-19 | 长兴进源新材料科技有限公司 | 一种2,2-双(4-氨基苯基)六氟丙烷合成方法 |
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003511378A (ja) * | 1999-10-07 | 2003-03-25 | アムジエン・インコーポレーテツド | トリアジン系キナーゼ阻害薬 |
HUP0301236A2 (hu) | 2000-06-28 | 2003-10-28 | Astrazeneca Ab, | Szubsztituált kinazolinszármazékok és felhasználásuk inhibitorokként |
US6864255B2 (en) * | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
SI1463506T1 (sl) | 2001-12-24 | 2010-01-29 | Astrazeneca Ab | Substituirani kinazolinski derivati kot inhibitorji kinaz Aurora |
CA2473510A1 (en) * | 2002-01-23 | 2003-07-31 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
JP2006506401A (ja) | 2002-05-23 | 2006-02-23 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害薬 |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
GB0219054D0 (en) | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
WO2004037814A1 (en) | 2002-10-25 | 2004-05-06 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
FR2853378B1 (fr) | 2003-04-02 | 2006-03-10 | Carbone Lorraine Composants | Plaquettes de frein a disque ventilees |
KR20060105872A (ko) * | 2003-12-29 | 2006-10-11 | 반유 세이야꾸 가부시끼가이샤 | 신규한 2-헤테로아릴 치환된 벤즈이미다졸 유도체 |
JP5097539B2 (ja) * | 2004-05-07 | 2012-12-12 | アムジエン・インコーポレーテツド | タンパク質キナーゼ調節剤および使用方法 |
JP5280862B2 (ja) * | 2006-01-23 | 2013-09-04 | アムジエン・インコーポレーテツド | オーロラキナーゼ調節剤および使用方法 |
-
2007
- 2007-01-22 JP JP2008551471A patent/JP5280862B2/ja active Active
- 2007-01-22 CA CA2637658A patent/CA2637658C/en active Active
- 2007-01-22 DK DK07716912.6T patent/DK1984353T3/en active
- 2007-01-22 ES ES11008953.9T patent/ES2502790T3/es active Active
- 2007-01-22 BR BRPI0706684-8A patent/BRPI0706684A2/pt not_active IP Right Cessation
- 2007-01-22 NZ NZ569815A patent/NZ569815A/en unknown
- 2007-01-22 GE GEAP200710871A patent/GEP20125643B/en unknown
- 2007-01-22 KR KR1020117025676A patent/KR101332975B1/ko active IP Right Grant
- 2007-01-22 WO PCT/US2007/001714 patent/WO2007087276A1/en active Application Filing
- 2007-01-22 HU HUE07716912A patent/HUE028504T2/en unknown
- 2007-01-22 EP EP07716912.6A patent/EP1984353B1/en active Active
- 2007-01-22 EA EA200801732A patent/EA018128B1/ru not_active IP Right Cessation
- 2007-01-22 MY MYPI20082661A patent/MY161884A/en unknown
- 2007-01-22 KR KR1020087020677A patent/KR101300424B1/ko active IP Right Grant
- 2007-01-22 AU AU2007208351A patent/AU2007208351C1/en active Active
-
2008
- 2008-07-14 IL IL192812A patent/IL192812A/en active IP Right Grant
- 2008-07-21 TN TNP2008000310A patent/TNSN08310A1/en unknown
- 2008-08-18 CR CR10213A patent/CR10213A/es unknown
- 2008-08-19 MA MA31184A patent/MA30224B1/fr unknown
- 2008-08-22 NO NO20083639A patent/NO20083639L/no not_active Application Discontinuation
-
2010
- 2010-11-05 AU AU2010241280A patent/AU2010241280B2/en active Active
-
2012
- 2012-08-08 HK HK12107815.4A patent/HK1167140A1/xx unknown
-
2013
- 2013-01-23 JP JP2013010303A patent/JP5753546B2/ja active Active
-
2016
- 2016-01-13 HR HRP20160039TT patent/HRP20160039T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160039T1 (hr) | Modulatori aurora kinaze i postupak uporabe | |
JP7261264B2 (ja) | 新規化合物 | |
JP7287967B2 (ja) | Tlr阻害剤として有効なアミノインドール化合物 | |
KR102056665B1 (ko) | 4,4,-이치환-1,4-디하이드로피리미딘 및 b형 간염의 치료를 위한 약제로서 이의 용도 | |
CA2682504A1 (en) | Aurora kinase modulators and method of use | |
JP6421241B2 (ja) | タンパク質キナーゼ阻害剤としての6−アミノ−7−ビシクロ−7−デアザ−プリン誘導体 | |
CN109843873B (zh) | 炔代杂环化合物、其制备方法及其在医药学上的应用 | |
CA2646952C (en) | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors | |
HRP20211406T1 (hr) | Biciklični heterociklični spojevi i njihove uporabe u liječenju | |
TW202122387A (zh) | Mta協同性之prmt5抑制劑 | |
CN108602818B (zh) | 吡唑稠环类衍生物、其制备方法及其在治疗癌症,炎症和免疫性疾病上的应用 | |
CN107074812B (zh) | 取代的嘧啶化合物 | |
RU2007130896A (ru) | Индольные производные для лечения вирусных инфекций | |
CA2642922A1 (en) | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | |
KR20100108390A (ko) | JAK2 억제제로서 유용한 피라졸로[1,5-a]피리미딘 | |
JP2013082757A (ja) | プロテインキナーゼ阻害薬として有用なベンズイミダゾール | |
KR20170075756A (ko) | 카르바졸 유도체 | |
EP3350185A1 (en) | 1-phenylpyrrolidin-2-one derivatives as perk inhibitors | |
EP3209665A1 (en) | Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors | |
JP2019529374A (ja) | 線維芽細胞増殖因子受容体の阻害剤及びそれらの使用 | |
CN114249712A (zh) | 嘧啶基衍生物、其制备方法及其用途 | |
CN112313207B (zh) | 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用 | |
CN104169258B (zh) | 用作激酶活性调节剂的新颖的杂环羧酰胺 | |
JP7330542B2 (ja) | キノリン構造を有するpan-KITキナーゼ阻害剤及びその適用 | |
TW202128646A (zh) | 氰基取代吡啶及氰基取代嘧啶類化合物、製備方法及其應用 |